Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates

This article was originally published in The Pink Sheet Daily

Executive Summary

The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.

You may also be interested in...

Aileron Overcoming Spirited Debate About Stapled Peptides

The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.

Roche Partners With Peptide Specialist Aileron For Five Targets

A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.

Corporate VC Funds Drive Innovation For Aileron’s Novel Stapled Peptide Technology

Aileron’s stapled peptides spark investment interest from four big pharma VC arms.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts